Evotec SE

EVTA

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    5,022

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,157.900.80-0.01%
CAC 408,087.1244.170.55%
DAX 4023,044.60152.920.67%
Dow JONES (US)41,985.3532.030.08%
FTSE 1008,689.1642.370.49%
HKSE23,905.56215.840.91%
NASDAQ17,784.0592.420.52%
Nikkei 22537,608.4968.57-0.18%
NZX 50 Index12,128.2114.670.12%
S&P 5005,667.564.670.08%
S&P/ASX 2007,936.905.700.07%
SSE Composite Index3,370.035.200.15%

Market Movers